Hospital
Temple University Hospital, INC
Temple University Hospital, INC was paid $4.01M by Medicaid between Jun 2020 and Dec 2024, across 68 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 53% of everything it billed.
33Billing provider infoTEMPLE UNIVERSITY HOSPITAL, INC
PHILADELPHIA, PA 19111
PHILADELPHIA, PA 19111
33aNPI1275157455assigned 06/03/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.01M
24GClaims44,385
24DCodes billed68
24AFirst – last monthJun 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#70 of 154
Median peer was paid$2.82M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 7,903 | $1.01M | |
| 2021 | 20,205 | $2.77M | |
| 2022 | 5,384 | $45K | |
| 2023 | 4,900 | $73K | |
| 2024incomplete | 5,993 | $108K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 53% | 1,211 | 959 | $2.12M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 7.7% | 2,413 | 1,586 | $308K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 6.6% | 290 | 135 | $263K |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 6.4% | 176 | 79 | $257K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.3% | 2,692 | 2,524 | $174K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 3.0% | 1,547 | 1,337 | $120K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 2.3% | 98 | 68 | $93K |
| J9202 | Goserelin acetate implant, per 3.6 mg | 1.8% | 216 | 201 | $73K |
| 96367 | 1.3% | 1,666 | 1,103 | $52K | |
| 99205 | Prolong outpt/office vis | 1.3% | 459 | 433 | $51K |
| 96417 | 1.2% | 697 | 521 | $47K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.1% | 1,057 | 989 | $43K |
56 more codes
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 1.1% | 18 | $43K |
| 96416 | 1.0% | 282 | $42K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 344 | $35K |
| 96415 | <1% | 727 | $29K | |
| 96411 | <1% | 354 | $25K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 3,403 | $24K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 34 | $21K |
| 80053 | Comprehensive metabolic panel | <1% | 2,318 | $19K |
| 36591 | <1% | 976 | $16K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 793 | $15K |
| 31575 | <1% | 42 | $14K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,387 | $14K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,562 | $12K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 704 | $12K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 161 | $9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 112 | $9K |
| 80050 | General health panel | <1% | 106 | $8K |
| 96402 | <1% | 200 | $6K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,499 | $6K |
| 99407 | <1% | 222 | $5K | |
| 83735 | <1% | 744 | $5K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 328 | $5K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 552 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,044 | $4K |
| 96368 | <1% | 373 | $3K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 404 | $3K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 408 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,079 | $2K |
| 99024 | <1% | 172 | $2K | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 225 | $2K |
| Q3014 | Telehealth originating site facility fee | <1% | 276 | $2K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 52 | $2K |
| 82378 | <1% | 97 | $1K | |
| 86304 | <1% | 28 | $689.66 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 169 | $655.50 |
| 91200 | <1% | 14 | $602.80 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 38 | $540.07 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 576 | $526.03 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,148 | $484.72 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 209 | $470.89 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 134 | $242.00 |
| 90686 | <1% | 14 | $234.36 | |
| 86850 | <1% | 27 | $165.88 | |
| 86901 | <1% | 27 | $113.68 | |
| 86900 | <1% | 27 | $112.34 | |
| 83615 | <1% | 16 | $55.75 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 27 | $9.70 |
| A9270 | Non-covered item or service | <1% | 20 | $4.16 |
| S0028 | Injection, famotidine, 20 mg | 0% | 537 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 297 | $0.00 |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 453 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 49 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 17 | $0.00 |
| 0001A | 0% | 13 | $0.00 | |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | 0% | 12 | $0.00 |
| J3490 | Unclassified drugs | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSNYDER, CHRISTOPHER (CFO)
Parent organizationTEMPLE UNIVERSITY HOSPITAL, INC
| Provider | Location | Paid |
|---|---|---|
| Temple University Hospital, INC | Philadelphia, PA | $116.55M |
| Temple University Hospital, INC - Psych Unit | Philadelphia, PA | $22.27M |
| Temple University Hospital, INC | Philadelphia, PA | $13.60M |
| CHH Community Health | Philadelphia, PA | $3.55M |
| Temple University Hospital, INC | Philadelphia, PA | $9K |
| Temple University Hospital, INC | Philadelphia, PA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.